Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive ... Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis; and NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology. It has a licensing agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc is based in London, the United Kingdom. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.005 | 2.85714285714 | 0.175 | 0.21 | 0.16625 | 17013888 | 0.19065847 | DE |
| 4 | 0 | 0 | 0.18 | 0.21 | 0.16625 | 16861748 | 0.19137889 | DE |
| 12 | -0.01 | -5.26315789474 | 0.19 | 0.245 | 0.1535 | 26618847 | 0.18798446 | DE |
| 26 | -0.075 | -29.4117647059 | 0.255 | 0.39 | 0.1535 | 34072784 | 0.21809603 | DE |
| 52 | 0.0875 | 94.5945945946 | 0.0925 | 0.55 | 0.0725 | 39872403 | 0.21626076 | DE |
| 156 | -0.05 | -21.7391304348 | 0.23 | 0.55 | 0.04 | 27554542 | 0.16061781 | DE |
| 260 | -1.92 | -91.4285714286 | 2.1 | 2.1 | 0.04 | 18480638 | 0.21955279 | DE |
Idunno
5分前
SSKILLZ1
6分前
SDCRBS
6分前
SSKILLZ1
8分前
SSKILLZ1
9分前
laraz5
10分前
SSKILLZ1
10分前
Wizzerd
12分前
SSKILLZ1
12分前
Sangrebandit
12分前
SDCRBS
12分前
don estaban
13分前
jerkviewer
14分前
LTR
15分前
DredLock
17分前
Lazy Oaks
18分前
DredLock
21分前
mdb1
21分前
Steady_T
22分前
TightCoil
24分前
SSKILLZ1
24分前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。